Reduction in requirements for allogeneic blood products: pharmacologic methods (Q40919601)

24 September 2017

1 reference

title

Reduction in requirements for allogeneic blood products: pharmacologic methods (English)

1 reference

24 September 2017

Janssens M

1

1 reference

24 September 2017

Hartstein G

series ordinal

2

1 reference

24 September 2017

David JL

series ordinal

3

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 December 1996

1 reference

The Annals of Thoracic Surgery

24 September 2017

published in

1 reference

24 September 2017

volume

62

1 reference

24 September 2017

issue

6

1 reference

24 September 2017

page(s)

1944-1950

1 reference

1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Desmopressin and blood loss after cardiac surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Prophylactic treatment of postperfusion bleeding using EACA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Decreased postoperative drainage with addition of epsilon-aminocaproic acid before cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

The dose-response relationship of tranexamic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Effect of aprotinin on need for blood transfusion after repeat open-heart surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Pharmacokinetics of aprotinin in preoperative cardiac surgical patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open-heart surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

The effects of aprotinin on hemostatic function during cardiac surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Aprotinin effect on platelet function and clotting during cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Aprotinin inhibits platelet adhesion to endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Aprotinin in cardiopulmonary bypass--effects on the Hageman factor (FXII)--Kallikrein system and blood loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

High-dose aprotinin therapy: a review of the first five years' experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Intraoperative coronary thrombosis: can aprotinin and protamine be incriminated?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Aprotinin for coronary artery bypass grafting: Effect on postoperative renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

IgE-mediated anaphylactic reaction to aprotinin during anaesthesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

inferred from DOI database lookup

7 January 2021

based on heuristic

The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2896%2900940-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0003-4975(96)00940-X

1 reference

24 September 2017

1 reference